BCX-1777 in Treating Patients With Refractory Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.

Key facts

Study ID

NCT00073944

Run by

BioCryst Pharmaceuticals

Starts

2003-04-01

Last updated by the study team

2013-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.